Keyphrases
Advanced Solid Tumors
100%
First-in-human Study
100%
Fibroblast Activation Protein
100%
4-1BB Agonists
100%
Atezolizumab
66%
Treatment Regimen
33%
Tumor
33%
Mechanism of Action
33%
Intravenous Dose
33%
Fixed-dose Combination
33%
Infiltration
33%
Ki-67
33%
Pharmacodynamics
33%
T Cell Activation
33%
T Cells
33%
Maximum Tolerated Dose
33%
Metastatic Tumor
33%
CD8+
33%
CD8+ T Cells
33%
Advanced or Metastatic
33%
Peripheral Blood
33%
Protein Binding Site
33%
Trimeric
33%
Complete Response
33%
Partial Response
33%
Gene Signature
33%
Dose-limiting Toxicity
33%
Pharmacokinetic Profile
33%
Dose-ranging
33%
Nonlinearity
33%
Activated T Cells
33%
Pneumonitis
33%
Febrile Neutropenia
33%
Solid Tumor Therapy
33%
Pharmacodynamic Biomarker
33%
Tumor Cell Death
33%
Anti-programmed Death 1
33%
Anti-programmed death-1 Monoclonal Antibody
33%
Immune Checkpoint Inhibitors
33%
4-1BB
33%
Immune-oncology
33%
Cytokine Release Syndrome
33%
Bispecific Fusion Protein
33%
CD137 Ligand
33%
Pharmacology, Toxicology and Pharmaceutical Science
Human Study
100%
Solid Malignant Neoplasm
100%
Neoplasm
66%
Pharmacodynamics
66%
CD8 Antigen
66%
Atezolizumab
66%
Biological Marker
33%
Elimination
33%
Pharmacokinetics
33%
Binding Site
33%
Pneumonia
33%
Maximum Tolerated Dose
33%
Febrile Neutropenia
33%
Fusion Protein
33%
Protein Binding
33%
Programmed Death 1 Ligand 1
33%
Immune Checkpoint Inhibitor
33%
CD137 Ligand
33%
Cytokine Release Syndrome
33%
Immunology and Microbiology
Fibroblast
100%
Agonist
100%
T Cell
66%
Pharmacodynamics
66%
Atezolizumab
66%
Protein Binding
33%
Arm
33%
Pharmacokinetics
33%
Upregulation
33%
T Cell Activation
33%
Cytotoxic T-Cell
33%
CD8
33%
Tumor Cell
33%
Binding Site
33%
Pneumonitis
33%
Programmed Death 1 Ligand 1
33%
Maximum Tolerated Dose
33%
Cell Killing
33%
CD137 Ligand
33%
Cytokine Release Syndrome
33%